SCHEMBL4135481

SCHEMBL4135481

FC(F)(F)c1cccc(C(c2ccccc2)N2CCNCC2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
OPRD1 P41143 8/20 0.63
OPRM1 P35372 3/20 0.63
OPRK1 P41145 3/20 0.63
OPRL1 P41146 3/20 0.63
SLC6A4 P31645 1/20 0.63
CACNA2D1 P54289 1/20 0.59
CACNA1B Q00975 1/20 0.59
CACNB1 Q02641 1/20 0.59
CACNA1C Q13936 1/20 0.59
HTR3E A5X5Y0 1/20 0.52
HTR3B O95264 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HTR1D P28221 1/20 0.52
HTR2C P28335 1/20 0.52
HTR3A P46098 1/20 0.52
HTR3D Q70Z44 1/20 0.52
HTR3C Q8WXA8 1/20 0.52
SIGMAR1 Q99720 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152093 0.96 SLC6A4 (0.60) MEN1KMT2AOPRD1OPRM1OPRK1
SCHEMBL14747925 0.89 MEN1 (0.62) MEN1KMT2AOPRD1OPRM1OPRK1
SCHEMBL1743579 0.87 MEN1 (0.72) MEN1KMT2AOPRD1OPRM1OPRK1
SCHEMBL10357009 0.86 TACR1 (0.53) MEN1KMT2AOPRD1OPRM1OPRK1
Hydrochloric Acid SCHEMBL5011277 0.85 MEN1 (0.70) MEN1KMT2AOPRD1OPRM1OPRK1
SCHEMBL4152584 0.83 SLC6A9 (0.61) MEN1KMT2AOPRD1OPRM1OPRK1
SCHEMBL219432 0.81 MEN1 (1.00) MEN1KMT2AOPRD1OPRM1SLC6A4
SCHEMBL2794662 0.81 MEN1 (1.00) MEN1KMT2AOPRD1OPRM1SLC6A4
SCHEMBL7101300 0.81 MEN1 (0.72) MEN1KMT2AOPRD1OPRM1OPRK1
SCHEMBL8964096 0.81 OPRD1 (0.57) MEN1KMT2AOPRD1OPRM1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2565183-A1 Glycine transporter-1 inhibitors Amgen Inc. (US) 2013-03-06 EP claimed
US-9663476-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2017-05-30 US disclosed
US-9663476-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2017-05-30 US disclosed
EP-2947067-A1 Glycine transporter-1 inhibitors Amgen, Inc (US) 2015-11-25 EP disclosed
EP-2947067-A1 Glycine transporter-1 inhibitors Amgen, Inc (US) 2015-11-25 EP disclosed
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2015-10-29 US disclosed
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2015-10-29 US disclosed
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 US disclosed
US-8735383-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2014-05-27 US disclosed
EP-2041088-B1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC (US) 2014-01-08 EP disclosed
US-7538114-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2009-05-26 US disclosed
US-7538114-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2009-05-26 US disclosed
EP-2041088-A1 GLYCINE TRANSPORTER-1 INHIBITORS Amgen Inc. (US) 2009-04-01 EP disclosed
WO-2008002583-A1 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2008-01-03 WO disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 US disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 US disclosed
US-20080004289-A1 Glycine transporter-1 inhibitors AMGEN INC. 2008-01-03 US disclosed
EP-1020443-B1 PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF AZWELL INC (JP) 2003-09-10 EP disclosed
US-6172228-B1 Process for producing piperazinesulfonamide derivatives and salts thereof AZWELL INC. (JP) 2001-01-09 US disclosed
EP-1020443-A1 PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF Azwell Inc. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004289-A1 Glycine transporter-1 inhibitors SLC18A2, SLC7A11, SLC6A5 MEN1 2625/4885KMT2A 843/4885OPRD1 2137/4885
US-20150307457-A1 GLYCINE TRANSPORTER-1 INHIBITORS SLC18A2, SLC7A11, SLC6A5 MEN1 2625/4885KMT2A 843/4885OPRD1 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.